Revised from my post yesterday.
Outlook:
Estimated cash outflows next quarter: $1,250m
R&D rebate amount: $354k
Debt Facility: $466k with zero drawn down
$2,946,000 - $1,250,000 = $1,696,000
$1,696,000 + $118,000 + $354,000 = $2,168,000
Very nice position. Let's see some human trials and more info on palatability.
Ann: PharmAust receives $354k R&D Tax Incentive Refund, page-2
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $34.31K | 195.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14336 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 96985 | 8 |
View Market Depth
| Last trade - 12.01pm 09/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |